Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 113-123

  Arias, Hugo R ^a   Fedorov, Nikolai B ^b   Benson, Lisa C ^b   Lippiello, Patrick M ^b   Gatto, Greg J ^b   Feuerbach, Dominik ^c,d   Ortells, Marcelo O ^c,d  

^a PLLC   (United States)

^b TARGACEPT INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSIDAD DE MORÓN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; NICOTINIC RECEPTOR ALPHA4BETA2; REBOXETINE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONFORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN INTERACTION;

ADRENERGIC UPTAKE INHIBITORS; ALKALOIDS; ANIMALS; AZOCINES; BICYCLO COMPOUNDS, HETEROCYCLIC; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGICAL PHENOMENA; EPITHELIAL CELLS; HEK293 CELLS; HUMANS; IMIPRAMINE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MORPHOLINES; NICOTINIC AGONISTS; PATCH-CLAMP TECHNIQUES; PYRIDINES; QUINOLIZINES; RADIOLIGAND ASSAY; RECEPTORS, NICOTINIC; TORPEDO;

EID: 84871684745     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.197905     Document Type: Article

References (39)

1. Albuquerque EX, Pereira EF, Alkondon M, and Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89: 73 - 120.
2. Andreasen JT, Nielsen EO, Christensen JK, Olsen GM, Peters D, Mirza NR, and Redrobe JP (2011) Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test. J Psychopharmacol 25 :1347-1356.
3. Arias HR (2010) Positive and negative modulation of nicotinic receptors. Adv Protein Chem Struct Biol 80:153-203.
4. Arias HR, Bhumireddy P, and Bouzat C (2006) Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int J Biochem Cell Biol 38:1254-1276.
5. Arias HR, Feuerbach D, Bhumireddy P, and Ortells MO (2010a) Inhibitory mechanisms and binding site location for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors. Int J Biochem Cell Biol 42:712-724.
6. Arias HR, Feuerbach D, Targowska-Duda KM, Russell M, and Jozwiak K (2010b) Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors. Biochemistry 49:5734-5742.
7. Arias HR, Gumilar F, Rosenberg A, Targowska-Duda KM, Feuerbach D, Jozwiak K, Moaddel R, Wainer IW, and Bouzat C (2009) Interaction of bupropion with muscletype nicotinic acetylcholine receptors in different conformational states. Biochemistry 48:4506-4518.
8. Arias HR, Rosenberg A, Targowska-Duda KM, Feuerbach D, Jozwiak K, Moaddel R, and Wainer IW (2010c) Tricyclic antidepressants and mecamylamine bind to different sites in the human alpha4beta2 nicotinic receptor ion channel. Int J Biochem Cell Biol 42:1007-1018.
9. Arias HR, Targowska-Duda KM, Feuerbach D, Sullivan CJ, Maciejewski R, and Jozwiak K (2010d) Different interaction between tricyclic antidepressants and mecamylamine with the human alpha3beta4 nicotinic acetylcholine receptor ion channel. Neurochem Int 56:642-649.
10. Brooks BR, Brooks CL, 3rd, and Mackerell AD, Jr, et al. (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30:1545-1614.
11. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
12. Fedorov NB, Benson LC, Graef J, Lippiello PM, and Bencherif M (2009) Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition. J Pharmacol Exp Ther 328:525-532.
13. Gerzanich V, Peng X, Wang F, Wells G, Anand R, Fletcher S, and Lindstrom J (1995) Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol 48:774-782.
14. Giniatullin RA, Sokolova EM, Di Angelantonio S, Skorinkin A, Talantova MV, and Nistri A (2000) Rapid relief of block by mecamylamine of neuronal nicotinic acetylcholine receptors of rat chromaffin cells in vitro: an electrophysiological and modeling study. Mol Pharmacol 58:778-787.
15. Gorman JM and Kent JM (1999) SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psych 60(Suppl 4):33-38.
16. Grubmüller H, Heymann B, and Tavan P (1996) Ligand binding: molecular mechanics calculation of the streptavidin-biotin rupture force. Science 271:997-999. (Pubitemid 26066398)
17. Gumilar F, Arias HR, Spitzmaul G, and Bouzat C (2003) Molecular mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic antidepressants. Neuropharmacology 45:964-976. (Pubitemid 37297922)
18. Gumilar F and Bouzat C (2008) Tricyclic antidepressants inhibit homomeric Cys-loop receptors by acting at different conformational states. Eur J Pharmacol 584:30-39.
19. Hajós M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, and Wong EH (2004) The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23-44. (Pubitemid 38381173)
20. Hennings EC, Kiss JP, De Oliveira K, Toth PT, and Vizi ES (1999) Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices. J Neurochem 73:1043-1050. (Pubitemid 29395460)
21. Izaguirre V, Fernández-Fernández JM, Ceña V, and González-García C (1997) Tricyclic antidepressants block cholinergic nicotinic receptors and ATP secretion in bovine chromaffin cells. FEBS Lett 418:39-42. (Pubitemid 27514411)
22. Liu Q, Yu KW, Chang YC, Lukas RJ, and Wu J (2008) Agonist-induced hump current production in heterologously-expressed human alpha4beta2-nicotinic acetylcholine receptors. Acta Pharmacol Sin 29:305-319. (Pubitemid 351316992)
23. López-Valdés HE and García-Colunga J (2001) Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake. Mol Psychiatry 6 :511-519.
24. Mathur A, Shankaracharya, and Vidyarthi AS (2011) SWIFT MODELLER: a Java based GUI for molecular modeling. J Mol Model 17:2601-2607.
25. Michelmore S, Croskery K, Nozulak J, Hoyer D, Longato R, Weber A, Bouhelal R, and Feuerbach D (2002) Study of the calcium dynamics of the human alpha4beta2, alpha3beta4 and alpha1beta1gammadelta nicotinic acetylcholine receptors. Naunyn Schmiedebergs Arch Pharmacol 366:235-245. (Pubitemid 34994918)
26. Miller DK, Wong EH, Chesnut MD, and Dwoskin LP (2002) Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 302:687-695. (Pubitemid 34787237)
27. Miyazawa A, Fujiyoshi Y, and Unwin N (2003) Structure and gating mechanism of the acetylcholine receptor pore. Nature 423:949-955. (Pubitemid 36806903)
28. Moore MA and McCarthy MP (1995) Snake venom toxins, unlike smaller antagonists, appear to stabilize a resting state conformation of the nicotinic acetylcholine receptor. Biochim Biophys Acta 1235:336-342.
29. Ohman D, Cherma MD, Norlander B, and Bengtsson F (2003) Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit 25:174-182. (Pubitemid 36373424)
30. Paterson NE, Semenova S, and Markou A (2008) The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. Psychopharmacology (Berl) 198:351-362.
31. Pedretti A, Villa L, and Vistoli G (2004) VEGA-an open platform to develop chemo-bio- informatics applications, using plug-in architecture and script programming. J Comput Aided Mol Des 18:167-173. (Pubitemid 39069412)
32. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, and Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802. (Pubitemid 43078511)
33. Picciotto MR, Brunzell DH, and Caldarone BJ (2002) Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 13:1097-1106. (Pubitemid 34722033)
34. Rana B, McMorn SO, Reeve HL, Wyatt CN, Vaughan PF, and Peers C (1993) Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine. Eur J Pharmacol 250:247-251. (Pubitemid 23357373)
35. Rauhut AS, Mullins SN, Dwoskin LP, and Bardo MT (2002) Reboxetine: attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Ther 303: 664-672. (Pubitemid 35231239)
36. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815. (Pubitemid 24007801)
37. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, and Sanberg PR (2002) Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7: 525-535.
38. Unwin N (2005) Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 346:967-989.
39. Zaitsev AV, Kim KK, Fedorova IM, Dorofeeva NA, Magazanik LG, and Tikhonov DB (2011) Specific mechanism of use-dependent channel block of calcium-permeable AMPA receptors provides activity-dependent inhibition of glutamatergic neurotransmission. J Physiol 589:1587-1601.